行情

AGLE

AGLE

Aeglea Bio
NASDAQ

实时行情|Nasdaq Last Sale

4.350
-0.020
-0.46%
已收盘, 16:00 04/02 EDT
开盘
4.330
昨收
4.370
最高
4.750
最低
4.070
成交量
8.25万
成交额
--
52周最高
9.10
52周最低
3.500
市值
1.27亿
市盈率(TTM)
-1.7774
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AGLE价格均价为17.86,最高价位26.00,最低价为10.00。

EPS

AGLE 新闻

更多
  • “50美分”交易员狂赚4亿美元后,将目标转向黄金
  • 新浪财经综合 · 53分钟前
  • 当两个明斯基过程遭遇大幅冲击:美国企业面临大考
  • 新浪财经-自媒体综合 · 54分钟前
  • 华尔街给美财政部“上课”:宽信用得看银行脸色
  • 界面新闻 · 1小时前
  • 瑞幸“造假门”后:中介机构或连坐 被监管纳入核查
  • 新浪财经 · 1小时前

所属板块

生物技术和医学研究
+3.33%
制药与医学研究
+2.80%

热门股票

代码
价格
涨跌幅

AGLE 简况

Aeglea BioTherapeutics, Inc. is a biotechnology company engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its lead product candidate, pegzilarginase, is engineered to degrade the amino acid arginine and is being developed to lower arginine levels in patients with Arginase I Deficiency. Its AEB4104 product candidate is a recombinant human enzyme that degrades the amino acid homocysteine and its oxidized form homocystine. It is developing AEB4104 for the treatment of patients with cystathionine beta synthase (CBS) deficiency. Its AEB5100 products candidate is a recombinant human enzyme that degrades plasma cystine and cysteine. It is developing AEB5100 product candidate for the treatment of patients with cystinuria. Its AEB3103 product candidate is an engineered human enzyme that targets the degradation of the amino acid cysteine/cystine.
展开

微牛提供Aeglea Bio Therapeutics Inc(NASDAQ-AGLE)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AGLE股票新闻,以帮助您做出投资决策。